PA
ALKT icon

PharVision Advisers’s Alkami Technology ALKT Stock Holding History

PharVision Advisers’s Portfolio ALKT Stock Details ALKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,581
Closed -$267K – 116
2025
Q4 		$267K Buy
+11,581
New +$256K 0.14% 347
2025
Q1 		– Sell
-7,097
Closed -$260K – 273
2024
Q4 		$260K Buy
+7,097
New +$265K 0.22% 200

Other funds holding ALKT

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
NRCM
North Reef Capital Management Laguna Beach, California $2.61B AUM 11.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JPM
JANA Partners Management New York $1.9B AUM 18.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AU
Algebris (UK) London, United Kingdom $1.52B AUM 3.09% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

PharVision Advisers's ALKT Position: Q1 2026 in Review

PharVision Advisers sold out of Alkami Technology (ALKT) in Q1 2026, closing a stake of 11,581 shares — an estimated $267K sold.

PharVision Advisers first reported a position in ALKT in Q4 2024 and held it in 2 quarters. The position peaked at $267K in Q4 2025. 211 funds tracked by Wall St. Rank hold ALKT as of Q1 2026.

  • PharVision Advisers reported no remaining Alkami Technology position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 11,581 Alkami Technology shares in Q1 2026, an estimated $267K.
  • PharVision Advisers first reported a position in Alkami Technology in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Alkami Technology position peaked at $267K in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Alkami Technology as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.